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Modulatorofapoptosis1(MOAP-1)isaBH3-likeproteinthatplayskeyrolesinboththeintrinsicandextrinsicmodesofcelldeath
or apoptosis. MOAP-1 is part of the Ras association domain family 1A (RASSF1A)/MOAP-1 pro-apoptotic extrinsic signaling
pathway that regulates apoptosis by utilizing death receptors such as tumor necrosis factor α (TNFα) or TNF-related apoptosis-
inducingligand(TRAIL)toinhibitabnormal growth.RASSF1Aisabonaﬁdetumorsuppressorgene thatisepigenetically silenced
by promoter-speciﬁc methylation in numerous human cancers. MOAP-1 is a downstream eﬀector of RASSF1A that promotes Bax
activation and cell death and is highly regulated during apoptosis. We speculate that MOAP-1 and RASSF1A are important
elements of an “apoptotic checkpoint” that directly inﬂuences the outcome of cell death. The failure to regulate this pro-apoptotic
pathway may result in the appearance of cancer and possibly other disorders. Although loss of RASSF1A expression is frequently
observed in human cancers, it is currently unknown if MOAP-1 expression may also be aﬀected during carcinogenesis to result in
uncontrolled malignant growth. In this article, we will summarize what is known about the biological role(s) of MOAP-1 and how
it functions as a downstream eﬀector to RASSF1A.
1.Introduction
Cancer is a disease of uncontrolled cell proliferation and is
the third leading causing of death worldwide following car-
diovascular and infectious diseases [2] .T h ea b n o r m a lp r o -
liferation of cells during cancer development results from a
multistep process involving the deregulation of genes that
promote cell growth (oncogenes) and those that normally
function to restrain growth (tumor suppressors). Interest-
ingly, approximately 90% of the genes that are associated
with cancer development have now been identiﬁed as being
tumor suppressors [3]. Moreover, many of these growth
inhibitory genes encode proteins that are involved in cell
death. RASSF1A has multiple biological functions including
the regulation of Bax-mediated cell death [4–6]. MOAP-1, a
highly regulated pro-apoptotic protein, serves a critical role
during mitochondrial-dependent apoptosis by inﬂuencing
and sustaining Bax activation [7, 8]. In this review, we will
discuss how MOAP-1 is regulated and how it serves as a
pivotal RASSF1A eﬀector protein to regulate cell death.
2.Apoptosis:ARegulatedBiologicalProcessto
Modulate Growth
A well-known mechanism of tumor suppression is the elimi-
nationofunwantedcellsthroughasequenceofeventsknown
as apoptosis [9]. The signiﬁcance of apoptosis in metazoan
biology is highlighted by the number of diseases that are
associated with its deregulation [10]. Apoptosis plays a crit-
ical role during the development of multicellular organisms
and adult tissue homeostasis and is vital to the removal of
damaged or dangerous cells. It can be initiated through two
main pathways in response to intracellular or extracellular
signals of cell death [11]. The intrinsic apoptotic signaling
pathway is activated in response to a diverse set of signals
originating from within cells due to cellular stresses such as
DNAdamage,hypoxia,toxins,orstarvation[12].Incontrast,
the extrinsic pathway of cell death is activated by the binding
of death-inducing ligands to death receptors.
Activation of the extrinsic apoptotic signaling path-
way occurs through cell surface death receptor/ligand2 Molecular Biology International
combinations that include TNF-R1/TNFα, Fas receptor (R)
(CD95/ APO-1)/Fas ligand, as well as TRAIL-R (1/2)/TRAIL
[13]. Activated death receptors trigger a series of events
resultingintheformationoftrimericreceptorcomplexesand
the death-inducing signaling complex (DISC) [14]. DISC as-
sembly and subsequent activation of initiator caspases
(mainly caspase-8) convey signals to the mitochondria to
promote the release of small molecules (such as cytochrome
c) from the mitochondrial matrix into the cytosol and the
assembly of the apoptosome complex to activate down-
stream eﬀector caspases (such as caspase-3) [15]. Intrinsic
pathway stimulation can also lead to cytochrome c release
and activation of eﬀector caspases. Once activated, eﬀector
caspases cleave several nuclear proteins [such as lamin B
and poly(ADP-ribose) polymerase] and activate speciﬁc
DNA endonucleases. These events result in many of the
biochemical and morphological changes observed during
apoptosis, including nuclear and cytoplasmic breakdown.
Mitochondria play an important role in the induction
of apoptosis through the release of proteins that promote
caspaseactivationandthebreakdownofcellularcomponents
[16]. Regulation of the mitochondrial events during apopto-
sisiscontrolledbyproteinsoftheB-celllymphoma-2(Bcl-2)
family and is composed of three diﬀerent subgroups known
as the anti-apoptotic, multidomain pro-apoptotic and BH3-
only proteins [12, 17]. The anti-apoptotic and BH3-only
proteinsareinvolvedininhibitingorpromotingthefunction
of multi-domain pro-apoptotic molecules, respectively. In
contrast,itismembersofthemultidomainsubgroupthatare
directly responsible for the mitochondrial outer membrane
permeabilization that occurs during apoptosis [18, 19]. Two
members from this group, Bax and Bak, are required for
apoptosis to occur [20]. Although the functions of Bax and
Bak are closely regulated by its Bcl-2 family members,
it is now known that, for at least Bax activation, other
proteins may also be involved in its modulation. One of
these molecules is the RASSF1A-binding protein, MOAP-1.
R A S S F 1 Af u n c t i o n st o“ o p e n ”M O A P - 1t oa l l o wf o rM O A P -
1-induced Bax conformational change by exposing the
epitope, 12GPTSSEQIMKTGA24, and allowing for the sub-
sequent insertion of Bax into the mitochondrial membrane.
Once inserted, Bax can cooperatively drive cell death in
association with Bak [21].
3.RasAssociationDomain Family
RASSF1A is a bona ﬁde tumor suppressor molecule that
serves as the founding member of the RASSF group of pro-
teins [22]. Currently, the RASSF protein family is comprised
of ten diﬀerent members known as RASSF1–10 that each
share the presence of a Ras association (RA) domain within
its primary amino acid sequence [23–26]. Of this protein
family, RASSF1 is the most thoroughly characterized and
studied thus far. A loss or decrease in RASSF1A expression
is frequently observed in a wide range of human cancers due
to epigenetic transcriptional silencing [27–30].
The tumor suppressor functions of RASSF1A include the
ability to regulate microtubule dynamics [31–33], mitosis
[32, 34–37], and apoptosis [5, 6, 38–41]. Due to the
particular focus of this paper, we will only discuss in de-
tail what is known about RASSF1A-dependent cell death
involving MOAP-1. It is now known that several pro-
apoptotic pathways can be modulated by RASSF1A. One
such pathway for the induction of RASSF1A-mediated apop-
tosis involves protein interactions with the Hippo signaling
components, serine/threonine kinases mammalian Ste20-
like (MST) 1 and 2 (reviewed separately in this issue). The
Hippo pathway is a conserved signaling pathway essential
for organ growth regulation in Drosophila and vertebrates
[42]. Currently, there is evidence to support the role for
RASSF1A in modulating the kinase activity of MST1/2 and
thus MST1/2-mediated cell death [38, 39]. RASSF1A can
also induce apoptosis through an MST2-speciﬁc pathway
by releasing MST2 from its inhibitor, Raf1, and allowing
f o rl a r g et u m o rs u p p r e s s o rh o m o l o gy( Drosophila)( L A T S ) 1 -
mediated activation of the transcriptional regulator Yes-
associatedprotein(YAP)1[41].Inturn,YAP1cantranslocate
to the nucleus and associate with the p73 transcription factor
in order to induce the transcription of pro-apoptotic gene
p53-upregulated modulator of apoptosis (PUMA) to aid in
Hippo-mediated cell death.
AsecondpathwayinvolvesMOAP-1.Inresponsetodeath
receptor signaling involving TNFα or TRAIL, RASSF1A can
associate with MOAP-1 in order to promote Bax conforma-
tional change, translocation and integration into the mito-
chondrial membrane to perturb mitochondrial permeability
[5, 6]. This is followed by the release of cytochrome c
to activate downstream caspases and to promote nuclear
and cytoplasmic breakdown. Furthermore, we speculate that
MOAP-1 may cooperate with RASSF1A to promote tumor
suppression. RASSF1A has been extensively reviewed in the
literature. In contrast, there are currently no reviews that
speciﬁcally address what is known about the biology of
MOAP-1. Indeed, MOAP-1 remains separate from the ca-
nonical group of Bax-regulatory molecules and therefore has
not garnered as much attention as the proteins of the Bcl-
2 family. In the remainder of this review, we will document
what is currently known about MOAP-1 and will discuss
evidence providing insight into the complexities of this
protein and its biological function(s).
4. Modulator of Apoptosis 1: A Brief History
MOAP-1 was ﬁrst reported as a mitochondria-enriched
39.5kDa molecule that was ﬁrst identiﬁed as a novel Bax-
associating protein in a yeast two-hybrid screen [7].
Located at genetic locus 14q32 (Figure 1), MOAP-1 is a
negatively charged protein that contains 351 amino acid
residues in humans and an isoelectric point (pI) of 4.939 at
pH 7.0 (Ensembl protein ID: ENST00000298894). MOAP-
1 is highly conserved in chimpanzee (Pan troglodytes),
rat (Rattus norvegicus)a n dm o u s e( Mus musculus), and
its coding sequence is contained within a single exon in
both mouse and humans (Figure 2). Since its discovery in
2001, research has established a central role for MOAP-1 in
both mitochondrial and death receptor-mediated apoptosis
[5, 8]. When overexpressed in mammalian cells, MOAP-
1 induces caspase-dependent apoptosis whereas MOAP-1Molecular Biology International 3
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Figure 1: Gene structure of human MOAP-1. The entire protein coding sequence of MOAP-1 is contained within exon 3 and
is located on the anti-sense strand of chromosome 14. Genbank accession: NM 022151.4. More information can be found at
http://www.ncbi.nlm.nih.gov/gene/64112. Numbers below schematic denote the size of the intron or exon.
knockdowncellsareresistanttoavarietyofapoptoticstimuli
including staurosporine, serum withdrawal, UV irradiation,
TNFα,a n dT R A I L[ 8]. Altogether, these results demonstrate
the importance of MOAP-1 in apoptosis and functions as a
key eﬀector of Bax conformational change and activation.
5. MOAP-1 ExpressioninNormal and
CancerCells
MOAP-1isaubiquitouslyexpressedproteinthatispresentat
moderate levels under normal cellular conditions and is con-
stitutively degraded by the ubiquitin-proteasome system [7,
43]. Given that RASSF1A expression is frequently lost during
carcinogenesis and Bax is mutated in a large percentage of
gastrointestinal and colorectal cancers, it is plausible that
MOAP-1 expression and/or function may also be regulated
duringcancerdevelopment[29,44,45].Indeed,immunohis-
tochemical analysis of MOAP-1 performed over a wide range
of human cancer tissues demonstrates either a negative or
a weak staining pattern for this protein (Table 1 and please
see site http://www.proteinatlas.org/search/moap1 under
“moap1 or pnma4” for immunohistochemical pictures of
MOAP-1 staining in numerous cancer cells). In support of
this immunohistochemical data, we have also found a loss
or reduction of MOAP-1 expression in an extensive panel of
cancer cell lines ranging from breast, brain, lung, skin and
blood cancers [Law et al., unpublished observations]. Fur-
thermore, in a classical xenograft assay, both RASSF1A and
MOAP-1 can suppress tumor formation in HCT116 colon
cancer cells suggesting tumor suppressor function (Figure
3) and functional importance for both genes in growth
inhibition in normal cells.
Currently, the mechanism responsible for the loss of
MOAP-1 expression in cancer cells remains unknown. It is
possible that expression changes in MOAP-1 may arise by
promoter speciﬁc epigenetic methylation, by miRNA/siRNA
regulation of the mRNA, and/or by alterations in MOAP-1
protein stability due to ubiquitin-directed proteolysis. The
MOAP-1 promoter displays 17 potential CpG islands that
Table 1: Summary of MOAP-1 staining patterns in human malig-
nanttissues.DatasourcewasTheHumanProteinAtlas(http://www
.proteinatlas.org/search/moap1) .A n t i b o d yu s e df o ra l lM O A P - 1
immunohistochemistry: Sigma-Aldrich HPA000939.
Cancer tissue type MOAP-1 staining pattern
Colorectal cancer Weak
Breast cancer Negative
Prostate cancer Negative
Ovarian cancer Negative
Cervical cancer Negative
Endometrial cancer Negative
Malignant carcinoid Negative
Head and neck cancer Negative
Thyroid cancer Negative
Malignant glioma Weak
Malignant lymphoma Negative
Lung cancer Weak
Malignant melanoma Negative
Skin cancer Negative
Testis cancer Moderate
Urothelial cancer Negative
Renal cancer Negative
Stomach cancer Weak
Pancreatic cancer Negative
Liver cancer Negative
may be epigenetically modiﬁed to result in loss of gene
expression, as suggested using MethPrimer online software
[46]. To date, no miRNA or siRNA has been identiﬁed
for MOAP-1 although we suspect that speciﬁc miRNA(s)
may exist to reduce or shut down MOAP-1 expression.
ThelastpotentialmechanismregulatingMOAP-1expression
is posttranslational modiﬁcation by ubiquitination and
degradationbytheproteasomaldegradationmachinery[43].
Future investigations will be required in order to understand4 Molecular Biology International
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Figure 2: A comparison of MOAP-1 orthologs. (a) Multiple sequence alignments of MOAP-1 orthologs present in human (h), mouse
(m), rat (r) and chimpanzee (c). Sequence alignments were performed using ClustalW2. NCBI reference sequences (mRNA and
protein): NM 022151.4 and NP 071434.2 (human); NM 022323.7 and NP 071718.1 (mouse); NM 001013101.1 and NP 001013119.1 (rat);
XM 510137.3 and XP 510137 (chimpanzee). (b) Percent amino acid identity between MOAP-1 orthologs calculated based on sequence
alignments in (2a). Analysis carried out using ClustalW2.
the ubiquitination of MOAP-1 and the biological outcome of
these ubiquitination events.
Like most disease-associated genes, polymorphisms may
exist to result in the loss of the encoded protein function.
Single nucleotide polymorphisms (SNPs) of MOAP-1 have
been documented in two databases suggesting disease-
associated changes [47, 48]. Although the population distri-
bution has not been determined as of yet, two somaticallyMolecular Biology International 5
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Figure 3: Tumor inhibiting potential of the RASSF1A/MOAP-1
tumor suppressor pathway. A classical xenograft assay was carried
out.Maleathymicnudemicewereinjectedsubcutaneouslywith1×
106 transiently transfected HCT116 cells mixed with matrigel mix
into the right and left ﬂank areas. Tumor volumes were measured
until day 35 and plotted. P values for MOAP-1 versus vector
(0.019);RASSF1Aversusvector(0.0001);MOAP-1versusRASSF1A
(0.02), n = 12–14. Statistical analysis was evaluated by Student’s t-
test (two-tailed). Protein expression at the time of subcutaneous
injection was conﬁrmed by immunoblotting (data not shown).
Protein expression in HCT116 cells can be detected up to 10 days
post-transfection. However, at the end of experiment, we could
not detect protein expression of HA-RASSF1A or Myc-MOAP-1
in the resulting tumors. We argue that the growth properties of
HCT116 cells containing the indicated expression constructs were
programmed within the ﬁrst 7–10 days and continued on that
program even though expression detection of the indicated genes
was not possible. Please refer to [1] for more details on this issue.
derived SNPs (resulting in a predicted amino acid change)
have been observed in melanoma patients—a proline to
serine change at amino acid 79 (P79S with a nucleotide
change of CCT → TCT) and an alanine to aspartic acid
change at position 335 (A335D with a nucleotide change of
GCT → GAT) [49]. Interestingly, the P79S polymorphism
may suggest the creation of a potentially novel serine
phosphorylation site to aﬀect the cell death properties of
MOAP-1, whereas A335D amino acid change would aﬀect
the TNF-R1-binding site on MOAP-1 (please see Figure 4).
Further veriﬁcation of these SNPs is warranted with respect
to penetrance within the normal and disease groups, origin
of these potential polymorphic changes, and their biological
signiﬁcance. Regardless of how MOAP-1 may lose expression
and/or function, we speculate that the combined loss of both
MOAP-1 and RASSF1A expression may be a common event
occurring during carcinogenesis to result in the functional
loss of the MOAP-1/RASSF1A cell death pathway and
enhanced proliferation of malignant cells. Furthermore, the
absence of MOAP-1 in cancer cells would also impact to
some extent on the intrinsic apoptotic pathway(s) where
MOAP-1 has been shown to play a role [8] and which is
also the target of many chemotherapeutic drugs. Future
investigations will be required in order to determine the
cause(s) underlying MOAP-1 expression changes in human
cancer.
Evidence from the literature indicates downregulation of
MOAP-1 expression in macrophage cells upon overexpres-
sion of the transcription factor MafB [50]. Upregulation of
MafB is commonly observed in alveolar macrophages that
havebeenexposedtocigarettesmoke,and,incidentally,these
cells also display increased viability [50, 51]. It has been pro-
posed that MafB may promote macrophage survival through
inhibition of apoptosis, which may be achieved through
downregulationofpro-apoptoticmoleculessuchasMOAP-1
[50].Inaddition,analysisofthepromoterregionofMOAP-1
for transcription factor binding sites identiﬁed several inter-
esting sites for NFκB (CCCTGGTCCC CAAGGAAATA CCT
GCAAAAG) and c-Rel (ATCGGAATGA CCCTCTCGGC)
and three sites for STAT1 (CTTGCTCCCT TAGGGGAACA)
using the online, publicly available Transcription Factor
Search (TFSEARCH) software. It remains to be determined
if these are functional transcription factor binding sites but
does provide hints to the complexity of MOAP-1 expression
and reaﬃrms its importance in both cell death and growth
control.
6. Interaction of MOAP-1 with Bcl-2
FamilyMembers
As a pro-apoptotic molecule, MOAP-1 selectively interacts
with members of the Bcl-2 protein family. In particular,
its association with Bax requires the presence of a Bcl-2
homology 3 (BH3)-like domain within amino acids 120–127
andthesamedomainisalsoessentialformediatingapoptosis
[7]. Interestingly, the association of MOAP-1 to Bax requires
all three BH (BH1, BH2, BH3) domains of the latter protein
and is thus in contrast to other known Bax-associating
partners(Figure 4).Additionally,itisspeculatedthatMOAP-
1 may associate at the hydrophobic cleft of Bax since critical
pointmutationsinanyofthethreeBHdomainsinBaxresult
in a loss of MOAP-1 association. The interaction between
MOAP-1 and Bax occurs upon induction of apoptosis in
response to activators of both the intrinsic and extrinsic cell
death pathways and facilitates the release of cytochrome c
from the mitochondria [8].
In addition to Bax, MOAP-1 also associates with the pro-
survival anti-apoptotic proteins Bcl-2 and Bcl-XL but not
additional Bcl-2 family members Bid, BimL, Bak, Bad or
Bcl-w under the same experimental conditions [7]. Evidence
suggests that its interactions with Bcl-2 and Bcl-XL may
function to restrain the pro-apoptotic activity of MOAP-1
since overexpression of Bcl-XL is suﬃcient to block MOAP-
1-mediated cell death. Therefore, it appears that MOAP-1
may function similar to the canonical BH3-only proteins of
the Bcl-2 family that are known to promote Bax activation
and which are also inhibited by its anti-apoptotic family
members.
7. Cooperation of MOAP-1 withRASSF1A in
DeathReceptor-MediatedApoptosis
MOAP-1 is required for execution of both the intrinsic and
extrinsic pathways of apoptosis where it is required for Bax6 Molecular Biology International
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Figure 5:MOAP-1cooperateswithRASSF1Aduringdeathreceptor-dependentapoptosisandpromotesBaxactivation.Inresponsetodeath
receptor stimulation, MOAP-1 is ﬁrst recruited to the receptor and then followed by RASSF1A association at the MOAP-1/receptor complex.
The association of MOAP-1 to RASSF1A promotes a conformational change in MOAP-1 that exposes its BH3-like domain required for Bax
association. The subsequent interaction between MOAP-1 and Bax induces a conformational change in Bax that enables its translocation,
and insertion into the mitochondrial outer membrane resulting in the release of cytochrome c and other apoptogenic factors, leading to
apoptosis.
conformationalchangeandtranslocationfromthe cytosolto
the mitochondria prior to the release of apoptogenic factors
[5, 8]. Although the mechanistic details of its role in the
intrinsicpathwayarecurrentlyunknown,thedeathreceptor-
dependent pathway involving MOAP-1 has been delineated
to a great extent [5, 6]( Figure 5).
Under nonstimulated conditions, MOAP-1 is normally
heldina“closed”conformationthroughanintraelectrostatic
interaction involving regions 178EEEF and 202KRRR [6].
However, stimulation of cells with TNFα or TRAIL results in
the recruitment of MOAP-1 to the receptor via a basic
sequence (336EEEEA) at its C-terminal end (Figures 4
and 5). Prior to death receptor association, RASSF1A is
released from association with 14-3-3 and loses its ability to
homodimerize [52]. Upon binding to the receptor through
its N-terminal cysteine-rich (C1) domain, RASSF1A induces
a conformational change in MOAP-1 to a more “open” state
(Figure 5, Signal 1, TNFα) that exposes its BH3-like domain
and allows it to bind and promote the activation of Bax [6].
The association of MOAP-1 with RASSF1A involves the
sequence 202KRRR in the former protein and 312EEEE in
the latter. Although activated K-Ras has been reported to be
required for stabilization of the MOAP-1/RASSF1A protein
complex [53], we are is able to consistently detect robust
associations between MOAP-1 and RASSF1A in experiments
that do not require the presence of overexpressed active K-
Ras [5, 6]. Therefore, we are currently unable to explain
or support the results of Vos and colleagues. Nonetheless,
MOAP-1-induced Bax conformational change enables Bax
to translocate from the cytosol to the mitochondria where it
can insert into the mitochondrial membrane and promote
the release of cytochrome c as well as other apoptosis-
inducing factors, resulting in cell death. Therefore, MOAP-
1 functions alongside RASSF1A as a key component linkingMolecular Biology International 7
deathreceptorsignalingtoBaxactivationandmitochondria-
associated cell death. The MOAP-1/RASSF1A pathway exists
asaseparate,parallelsignalingcascadethatlinkstheextrinsic
and intrinsic pathways of apoptosis independent of tBid and
caspase 8 [5].
In addition toRASSF1A, MOAP-1hasalsodemonstrated
the ability to associate with a second RASSF family member,
RASSF6[54].TheinteractionbetweenRASSF6andMOAP-1
is enhanced by the presence of activated K-Ras, and, further-
more,RASSF6isalsoabletopromoteapoptosis.Therefore,it
has been speculated that Ras may activate the pro-apoptotic
function of RASSF6 and that RASSF6 may cooperate with
MOAP-1in a pathway similar to RASSF1A in order to induce
cell death. However, this hypothesis still needs to be veriﬁed.
8. Regulation of MOAP-1 Stability by
Apoptotic Signals
Under nonstimulated conditions, MOAP-1 is constitutively
degraded by the ubiquitin-proteasome system and is nor-
mally a short-lived protein with a half-life of approximately
25minutes[43].However,evidencesuggeststhattargetingof
MOAP-1 to the proteasome may involve an unconventional
mechanism given that no speciﬁc lysine residue can be
identiﬁed as the site of polyubiquitination [43]. Indeed,
mutation of any individual lysine residue or combination of
residues fails to abolish MOAP-1 ubiquitination. Thus, the
process involved in controlling MOAP-1 turnover remains to
be determined.
In addition to regulation of basal MOAP-1 expression,
MOAP-1 is also rapidly upregulated in response to multiple
apoptotic stimuli including serum withdrawal, etoposide,
TRAIL,andtheendoplasmicreticulumstressinducerthapsi-
gargin [43]. The increase in MOAP-1 protein arises through
inhibition of its polyubiquitination and subsequent pro-
teasomal degradation. Research ﬁndings demonstrate that
elevation of MOAP-1 levels occurs prior to cell commitment
to apoptosis and that the stabilization of MOAP-1 helps to
sensitizecellstoapoptosisbyincreasingthelevelsofactivated
Bax.
Intriguingly, stabilization of MOAP-1 in response to
apoptosis employs the RING domain protein tripartite motif
containing 39 (TRIM39) [55]. TRIM39 has not yet been
functionally characterized but belongs to the tripartite motif
(TRIM) family of proteins that are commonly involved in
innate immunity [56] and contains three zinc-binding do-
mains including a RING, B box, and coiled-coil region. Al-
though a large number of proteins that contain RING
domains also function as E3 ligases [57], TRIM39 associates
with MOAP-1 in a manner that promotes its stabilization
rather than its polyubiquitination [55]. TRIM39 also sensi-
tizes cells to apoptosis by inhibiting MOAP-1 ubiquitination
(through an unknown mechanism) and thus allows for the
accumulation of MOAP-1 that can then can activate Bax.
Furthermore,itwasobservedthatbothTRIM39andMOAP-
1 inﬂuence each other’s localization to the mitochondria
when overexpressed in HEK293 cells [55]. The upregulation
of MOAP-1 protein levels can also occur in response to
chemical toxins and clinical drugs reaﬃrming our specu-
lation that MOAP-1 in cancer cells may be important for
patient response to certain chemotherapeutic treatments
[58]. Incubation of chronic lymphocytic leukemia cells
with the apoptosis-inducing compound 5-aminoimidazole-
4-carboxamideriboside or acadesine (AICAR) has been
shown to result in a signiﬁcant increase in MOAP-1 expres-
sion [58]. Although the pathway through which AICAR
induces cell death remains unknown, it is achieved through a
mechanism that is independent of both AMPK and p53. In a
second example, the addition of the novel immunosuppres-
sant 2-amino-2[2-(4-octylphenyl) ethyl]-1,3-propane-diol
hydrochloride (FTY720) to Jurkat cells results in a greater
than tenfold upregulation of MOAP-1 mRNA levels [59]. It
is believed that the potent immunosuppressive function of
FTY720 may be attributed to its ability to induce lymphocyte
apoptosis [60]. However, FTY720 has also been shown to
induceapoptosisinavarietyofdiﬀerentcancercelltypesand
to prevent breast cancer metastasis in mouse models [61–
64]. Thus, it is plausible that the immunosuppressive and/or
antitumorigenic eﬀects of FTY720 may be partially mediated
by MOAP-1.
We have evidence for a nondegradative ubiquitination
of MOAP-1. This post-translational modiﬁcation proceeds
through a mechanism that is responsive to death receptor
stimulation and a novel protein kinase C (PKC) dependent
event [Law et al, unpublished observations] that may allow
MOAP-1 to associate with and promote Bax activation
(Figure 5, Signal 2). Interestingly, MOAP-1 has two potential
binding sites for TRAF2, an E3-ubiquitin ligase impor-
tant for TNF-R1-dependent signaling. These sites are at
178EPGEEFGRW AND 331DYEAAEEEAL with the under-
lined residues forming the core of the TRAF2 association
site [64]. The ﬁrst potential site is part of the intraelectro-
static pair that overlaps with the BH3-domain of MOAP-
1. We are currently investigating the possible involvement
of TRAF2 in MOAP-1 ubiquitination and the functional
importance of several potential lysine residues for ubiquitin-
dependent modiﬁcation. We speculate that the ubiquitina-
tion of MOAP-1 may inﬂuence MOAP-1-mediated growth
suppression and/or MOAP-1-directed apoptosis. This form
of MOAP-1ubiquitination adds to the complexity of MOAP-
1 stability by a degradative-dependent ubiquitination to
modulate the biological functions of MOAP-1.
9. MOAP-1: AParaneoplastic Antigen
In addition to its role as a pro-apoptotic molecule, MOAP-1
is also the fourth member of the paraneoplastic Ma antigen
(PNMA) family and is consequently also known as PNMA4.
Paraneoplastic antigens (also termed “onconeural antigens”)
are proteins that are restricted in expression to immune-
privileged sites within the body (such as the brain) and are
therefore recognized as foreign molecules by the immune
system when aberrantly expressed at other sites [65, 66].
Remarkably, these foreign proteins are expressed by systemic
tumors in a subset of cancer patients which subsequently
trigger an immune-mediated antitumor response. In some
patients, this immune response is not only directed against8 Molecular Biology International
the tumor itself but also towards the sites within the body
that ordinarily express the protein. In the case of the brain,
this immune response results in neuronal degeneration
and the development of an autoimmune neurologic disease
known as a paraneoplastic neurological disorder (PND).
The PNMA family consists of six members (PNMAs 1–
6) that, with the exceptions of PNMAs 4, 5, and 6, were
originally identiﬁed through screening of complementary
DNA libraries using antibody-containing sera from patients
with PNDs [67]. Although MOAP-1/PNMA4 is ubiquitously
expressed with higher levels in the heart and brain [7],
each of the other family members are more restricted in
expression [67–71]. The detection of antibodies to PNMAs
1–3 in PND patients is associated with disorders aﬀectingthe
limbic system, brain, stem and cerebellum but is not
indicative of any particular cancer type [68–70, 72]. In
contrast, MOAP-1 has a well-established role in apoptosis
and—similar to PNMA5 and PNMA6—is not associated
with the development of PNDs to date. MOAP-1 displays
the greatest amino acid sequence homology with PNMA1
(58%) which functions as a neuronal-speciﬁc pro-apoptotic
molecule [73]. PNMA1 contains both a BH3-like domain
and a conserved RASSF1A association site similar to that
found on MOAP-1 (Figure 4). However, PNMA1 does not
associate with either Bax or RASSF1A [73], and, therefore,
although unknown, the mechanism by which it induces
cell death presumably diﬀers from MOAP-1. It remains to
be determined how, and if, MOAP-1 may impinge on the
pathogenesis of paraneoplastic syndromes.
10. Concluding Remarks
MOAP-1 is a highly regulated pro-apoptotic molecule that
demonstrates multiple potential properties of a candidate
tumor suppressor protein. Given that MOAP-1 regulates
RASSF1A pro-apoptotic function and RASSF1A is also
epigeneticallysilencedinalargenumberofhumancancers,it
is possible that the combined loss of MOAP-1 and RASSF1A
during carcinogenesis may result in the inhibition of extrin-
sically activated cell death signaling pathways in cancer cells.
RASSF1A has now been demonstrated to inﬂuence several
other biological processes such as cell cycle, microtubule
dynamics,andcellmigration. Therefore,it willbe interesting
to explore which of these biological processes MOAP-1 may
alsobeinvolvedinandthatmaybeimportantforittobehave
as a potential tumor suppressor protein.
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